曾正陪,陈康

• 1:中国医学科学院北京协和医学院北京协和医院内分泌科
• 2:中国人民解放军总医院第一医学中心内分泌科

摘要(Abstract)：

<正>原发性醛固酮增多症（原醛症）是继发性高血压常见的内分泌肾上腺性高血压，近年来随着对该病认识的提高，激素检测技术的快速发展，报告其患病率明显增高~([1-5])。2020年美国一项横断面研究以口服钠抑制试验时测定尿醛固酮水平>12μg/24 h为诊断标准，在血压正常、Ⅰ级、Ⅱ级和难治性高血压患者中的原醛症患病率分别为11.3%、15.7%、21.6%和22.0%~([6])。

关键词(KeyWords)： 原发性醛固酮增多症;醛固酮瘤;肾上腺增生;肾上腺肿瘤消融术;肾上腺动脉栓塞术

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 曾正陪,陈康

参考文献(References)：

• [1] Mosso L,Carvajal C,Gonzulez A,et al. Primary aldosteronism and hypertensive disease[J]. Hypertension,2003,42(2):161-165.
• [2] Calhoun DA. Is there an unrecognized epidemic of primary aldosteronism[J]? Pro Hypertension,2007,50(3):447-453.
• [3] Loh KC,Koay ES,Khaw MC,et al. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore[J].J Clin Endocrinol Metab,2000,85(8):2854-2859.
• [4] Sang X,Jiang Y,Wang W,et al. Prevalence of and risk factors for primary aldosteronism among patients with resistant hypertension in China[J]. J Hypertens,2013,31(7):1465-1471.
• [5] Xu Z,Yang J,Hu J,et al. Primary aldosteronism in patients in China with recently detected hypertension[J]. J Am Coll Cardiol,2020,75(16):1913-1922.
• [6] Brown JM,Siddiqui M,Calhoun DA,et al. The unrecognized prevalence of primary aldosteronism:a cross-sectional study[J]. Ann Intern Med,2020,173(1):10-20.
• [7]中华医学会内分泌学分会.原发性醛固酮增多症诊断治疗的专家共识（2020版）[J].中华内分泌代谢杂志，2020,36(9):727-736.
• [8] Funder JW,Carey RM,Mantero F,et al. The management of primary aldosteronism:case detection,diagnosis,and treatment:an Endocrine Society clinical practice guideline[J].J Clin Endocrinol Metab,2016,101(5):1889-1916.
• [9] Williams TA,Lenders JWM,Mulatero P,et al. Outcomes after adrenalectomy for unilateral primary aldosteronism:an international consensus on outcome measures and analysis of remission rates in an international cohort[J]. Lancet Diabetes Endocrinol,2017,5(9):689-699.
• [10] Williams TA,Reincke M. Diagnosis and management of primary aldosteronism:the Endocrine Society guideline 2016 revisited[J].Eur J Endocrinol,2018,179(1):R19-R29.
• [11] Naruse M,Katabami T,Shibata H,et al. Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021[J]. Endocr J,2022,69(4):327-359.
• [12] Karagiannis A,Tziomalos K,Papageorgiou A,et al.Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism[J]. Expert Opin Pharmacother,2008,9(4):509-515.
• [13] Zhang H,Li Q,Liu X,et al. Adrenal artery ablation for primary aldosteronism without apparent aldosteronoma:an efficacy and safety,proof-of principle trial[J]. J Clin Hypertens(Greenwich),2020,22(9):1618-1626.
• [14] Zhao Z,Liu X,Zhang H,et al. Catheter-based adrenal ablation remits primary aldosteronism:a randomized medicationcontrolled trial[J]. Circulation,2021,144(7):580-582.
• [15]祝之明，赵志钢，张和轩，等.肾上腺消融术治疗原发性醛固酮增多症相关难治性高血压：技术关键与应用前景[J].中华心血管病杂志，2021,49(10):951-956.
• [16] Bouhanicka B,Delchierb MC,Lagardeb S,et al.Radiofrequency ablation for adenoma in patients with primary aldosteronism and hypertension:ADERADHTA,a pilot study[J].J Hypertens,2021,39(4):759-765.
• [17]中国医师协会介入医师分会肿瘤消融专业委员会，中国临床肿瘤学会肿瘤消融治疗专家委员会.影像引导下肾上腺肿瘤消融治疗专家共识（2019版）[J].中华医学杂志，2019,99(15):1123-1132.
• [18]张媛，李鹏，游苏宁.医学期刊指南共识类文章引证特征分析及对选题策划的指导作用[J].中国科技期刊研究，2022,33(4):538-544.
• [19] Park BK,Fujimori M,Shen SH,et al. A sian conference on tumor ablation guidelines for adrenal tumor ablation[J].Endocrinol Metab(Seoul),2021,36(3):553-563.
• [20] Frenk NE,Daye D,Tuncali K,et al. Local control and survival after image-guided percutaneous ablation of adrenal metastases[J].J Vasc Interv Radiol,2018,29(2):276-284.
• [21] Fassnacht M,Dekkers OM,Else T,et al. European society of endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults,in collaboration with the European network for the study of adrenal tumors[J].Eur J Endocrinol,2018,179(4):G1-G46.
• [22] Donlon PT,Fallahi H,Beard WL,et al. Using microwave thermal ablation to develop a subtotal,cortical-sparing approach to the management of primary aldosteronism[J]. Int J Hyperthermia,2019,36(1):904-913.
• [23] Sarwar A, Brook OR, Vaidya A, et al. Clinical outcomes following percutaneous radiofrequency ablation of unilateral aldosterone-producing adenoma:comparison with adrenalectomy[J]. J Vasc Interv Radiol,2016,27(7):961-967.
• [24] Yang MH,Tyan YS,Huang YH,et al. Comparison o f radiofrequency ablation versus laparoscopic adrenalectomy for benign aldosterone-producing adenoma[J]. Radiol Med,2016,121(10):811-819.
• [25] Liu SY,Chu CM,Kong AP,et al. Radiofrequency ablation compared with laparoscopic adrenalectomy for aldosterone-producing adenoma[J]. Br J Surg,2016,103(11):1476-1486.
• [26] Va n der Walt IS,Brown M,Lodh S. Adrenal gland-sparing transcatheter embolisation of an aldosteronoma for the treatment of refractory hypertension[J]. Radiol Case Rep,2022,17(4):1088-1094.
• [27] Hokotate H,Inoue H,Baba Y,et al. Aldosteronomas:experience with superselective adrenal arterial embolization in 33cases[J]. Radiology,2003,227(2):401-406.
• [28]宁光，许曼音，陈家伦.原发性醛固酮增多症[M]//陈家伦.临床内分泌学.上海：上海科学技术出版社，2011:555-564.
• [29] Stephen AE,Haynes AB,Hodin RA. Adrenal surgery[M]//Blake MA, Boland GWL. Adrenal imaging. Germany:Humana Press,2009:80.
• [30] Williams TA,Gomez-Sanchez CE,Rainey WE,et a l. International histopathology consensus for unilateral primary aldosteronism[J]. J Clin Endocrinol Metab,2021,106(1):42-54.
• [31] Lim V,Guo Q,Grant CS,et al. Accuracy of adrenal imaging and adrenal venous sampling in predicting surgical cure of primary aldosteronism[J]. J Clin Endocrinol Metab,2014,99(8):2712-2719.
• [32]国家限制类技术目录（2022年版）[R].发布机构：中华人民共和国国家卫生健康委员会.发布日期：2022-04-20.